Correlation between estrogen deficiency and non-alcoholic fatty liver disease in female patients
- Authors: Dora S.V.1, Khalimov Y.S.1, Mekhtiev S.N.1, Lisker A.V.1, Zimina M.V.1, Semikova G.V.1, Volkova A.R.1, Cherebillo I.V.1, Polyakova Y.V.1
-
Affiliations:
- Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia
- Issue: Vol 10, No 8 (2024)
- Pages: 8-15
- Section: ORIGINAL STUDIES
- URL: https://journals.rcsi.science/2412-4036/article/view/271106
- DOI: https://doi.org/10.18565/therapy.2024.8.8-15
- ID: 271106
Cite item
Open Access
Access granted
Subscription Access
Abstract
Abstract. In recent years, the role of hypoestrogenemia as an independent risk factor for the development and progression of non-alcoholic fatty liver disease (NAFLD) has been actively discussed, but this correlation has been poorly studied.
The aim: to study the frequency and severity of liver steatosis in female patients with premature ovarian failure (POF).
Material and methods. The study included 86 non-obese female patients aged 29–40 years, who were divided into three groups: group 1 (control, n = 40) – females with a regular menstrual cycle (MC) and normal levels of follicle-stimulating hormone (FSH) and estradiol; group 2 (n = 29) – females who had not had menstruation for more than 3 months and had an increased FSH level; group 3 (n = 17) – females with premature menopause (PM). On days 3–5 of the menstrual cycle, blood sampling was taken and the following parameters were assessed: FSH, estradiol, glucose, insulin, triglycerides, low- and high-density lipoproteins, total cholesterol, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase. Waist circumference (WC) was measured, body mass index, HOMA-IR index, and liver steatosis coefficient FLI (Fatty Liver Index) were calculated, and an ultrasound examination (US) of liver was performed.
Results. As estrogen deficiency increased, the examined females showed a significant increase in WC (p = 0.001). Patients with estrogen deficiency had significantly worse carbohydrate metabolism and lipid profile. Liver function tests were significantly higher in the group of female patients with PM. FLI coefficient was 30.0 and 41.5 in patients of groups 2 and 3, respectively, versus 9.0 in group 1 (control). A negative correlation was found between the estradiol level and FLI coefficient (r = -0.524; p 0.001). FLI index became more sensitive than ultrasound data for assessing the degree of steatosis and NAFLD incidence.
Conclusion. PM negatively affects female’s metabolic health. Early diagnosis and prevention of NAFLD in female patients with POF will prevent irreversible liver changes and reduce the risk of cardiovascular complications.
Full Text
##article.viewOnOriginalSite##About the authors
Svetlana V. Dora
Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia
Author for correspondence.
Email: doras2001@mail.ru
ORCID iD: 0000-0002-8249-6075
SPIN-code: 9845-0065
MD, Dr. Sci. (Medicine), professor
Russian Federation, Saint PetersburgYuri Sh. Khalimov
Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia
Email: yushkha@gmail.com
ORCID iD: 0000-0002-7755-7275
SPIN-code: 7315-6746
MD, Dr. Sci. (Medicine), professor
Russian Federation, Saint PetersburgSabir N. Mekhtiev
Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia
Email: sabirm@mail.ru
ORCID iD: 0000-0001-7367-9219
MD, Dr. Sci. (Medicine), professor
Russian Federation, Saint PetersburgAnna V. Lisker
Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia
Email: a.lisker@mail.ru
MD, PhD (Medicine)
Russian Federation, Saint PetersburgMargarita V. Zimina
Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia
Email: rita.zimina.1997@mail.ru
ORCID iD: 0009-0006-5004-2825
MD
Russian Federation, Saint PetersburgGalina V. Semikova
Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia
Email: semikovagv@yandex.ru
ORCID iD: 0000-0003-0791-4705
MD, PhD (Medicine), assistant
Russian FederationAnna R. Volkova
Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia
Email: volkovaa@mail.ru
ORCID iD: 0000-0002-5189-9365
SPIN-code: 4007-1288
MD, Dr. Sci. (Medicine), professor
Russian Federation, Saint PetersburgIrina V. Cherebillo
Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia
Email: icherebillo@yandex.ru
ORCID iD: 0009-0000-7067-296X
MD, clinical resident
Russian Federation, Saint PetersburgYulia V. Polyakova
Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia
Email: cumparsita01@gmail.com
ORCID iD: 0009-0008-0013-9615
student
Russian Federation, Saint PetersburgReferences
- Li M., Zhu Y., Wei J. et al. The global prevalence of premature ovarian insufficiency: A systematic review and meta-analysis. Climacteric. 2023; 26(2): 95–102. https://doi.org/10.1080/13697137.2022.2153033. PMID: 36519275.
- Rudnicka E., Kruszewska J., Klicka K. et al. Premature ovarian insufficiency – aetiopathology, epidemiology, and diagnostic evaluation. Prz Menopauzalny. 2018; 17(3): 105–8. https://doi.org/10.5114/pm.2018.78550. PMID: 30357004. PMCID: PMC6196779.
- Golezar S., Ramezani T.F., Khazaei S. et al. The global prevalence of primary ovarian insufficiency and early menopause: A meta-analysis. Climacteric. 2019; 22(4): 403–11. https://doi.org/10.1080/13697137.2019.1574738. PMID: 30829083.
- Кравченко Е.Н., Воронцова М.С. Преждевременная недостаточность яичников, современный взгляд на проблему. Мать и дитя в Кузбассе. 2022; (1): 4–10. [Kravchenko E.N., Vorontsova M.S. Premature ovarian insufficiency: Modern view of the problem. Mat’ i ditja v Kuzbasse = Mother and Baby in Kuzbass. 2022; (1): 4–10 (In Russ.)]. https://doi.org/10.24412/2686-7338-2022-1-4-10. EDN: JSNSON.
- Ивашкин В.Т., Драпкина О.М., Маев И.В. с соавт. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015; 25(6): 31–41. [Ivashkin V.T., Drapkina O.M., Mayev I.V. et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the russian federation: DIREG 2 study results. Rossiiskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology and Coloproctology. 2015; 25(6): 31–41 (In Russ.)]. https://doi.org/10.21638/11701/spbu11.2017.201. EDN: VOXFQP.
- Targher G., Byrne C.D., Lonardo A. et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016; 65(3): 589–600. https://doi.org/10.1016/j.jhep.2016.05.013. PMID: 27212244.
- Hamaguchi M., Kojima T., Takeda N. et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007; 13(10): 1579–84. https://doi.org/10.3748/wjg.v13.i10.1579. PMID: 17461452. PMCID: PMC4146902.
- Киселева Е.В., Демидова Т.Ю. Неалкогольная жировая болезнь печени и сахарный диабет 2 типа: проблема сопряженности и этапности развития. Ожирение и метаболизм. 2021; 18(3): 313–319. [Kiseleva E.V., Demidova T.Yu. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The problem of conjunction and phasing. Ozhirenie i metabolizm = Obesity and Metabolism. 2021; 18(3): 313–319 (In Russ.)]. https://doi.org/10.14341/omet12758. EDN: UKMSSN.
- Ballestri S., Nascimbeni F., Baldelli E. et al. NAFLD as a sexual dimorphic disease: Role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther. 2017; 34(6): 1291–1326. https://doi.org/10.1007/s12325-017-0556-1. PMID: 28526997. PMCID: PMC5487879.
- Wang Y., Wu C., Zhou J. et al. Overexpression of estrogen receptor β inhibits cellular functions of human hepatic stellate cells and promotes the anti-fibrosis effect of calycosin via inhibiting STAT3 phosphorylation. BMC Pharmacol Toxicol. 2022; 23(1): 77. https://doi.org/10.1186/s40360-022-00617-y. PMID: 36207725. PMCID: PMC9541055.
- Zhou Y., Shimizu I., Lu G. et al. Hepatic stellate cells contain the functional estrogen receptor beta but not the estrogen receptor alpha in male and female rats. Biochem Biophys Res Commun. 2001; 286(5): 1059–65. https://doi.org/10.1006/bbrc.2001.5479. PMID: 11527408.
- Liu Q.-H., Li D.-G., Huang X. et al. Suppressive effects of 17 beta-estradiol on hepatic fibrosis in CCl4-induced rat model. World J Gastroenterol. 2004; 10(9): 1315–20. https://doi.org/10.3748/wjg.v10.i9.1315. PMID: 15112349. PMCID: PMC4622773.
- Yoneda M., Thomas E., Sumida Y. et al. The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease. Hepatology. 2014; 60(5): 1792. https://doi.org/10.1002/hep.27097. PMID: 24585422.
- Кологривова И.В., Винницкая И.В., Кошельская О.А., Суслова Т.Е. Висцеральное ожирение и кардиометаболический риск: особенности гормональной и иммунной регуляции. Ожирение и метаболизм. 2017; 14(3): 3–10. [Kologrivova I.V., Vinnitskaya I.V., Koshelskaya O.A., Suslova T.E. Visceral obesity and cardiometabolic risk: Features of hormonal and immune regulation. Ozhirenie i metabolizm = Obesity and Metabolism. 2017; 14(3): 3–10 (In Russ.)]. https://doi.org/10.14341/omet201733-10. EDN: YLAUGQ.
- Venetsanaki V., Polyzos S.A. Menopause and non-alcoholic fatty liver disease: A review focusing on therapeutic perspectives. Curr Vasc Pharmacol. 2019; 17(6): 546–55. https://doi.org/10.2174/1570161116666180711121949. PMID: 29992886.
- Xin G., Qin S., Wang S. et al. Sex hormone affects the severity of nonalcoholic steatohepatitis through the MyD88-dependent IL-6 signaling pathway. Exp Biol Med (Maywood). 2015; 240(10): 1279–86. https://doi.org/10.1177/1535370215570189. PMID: 25790822. PMCID: PMC4935253.
- Gunning M.N., Meun C., van Rijn B.B. et al. Coronary artery calcification in middle-aged women with premature ovarian insufficiency. Clin Endocrinol (Oxf). 2019; 91(2): 314–22. https://doi.org/10.1111/cen.14003. PMID: 31049984.
- Булатова И.А., Шевлюкова Т.П., Гуляева И.Л. с соавт. Особенности течения неалкогольного стеатоза печени у женщин репродуктивного возраста и в менопаузе. Медицинский совет. 2022; 16(15): 62–69. [Bulatova I.A., Shevlyukova T.P., Gulyaeva I.L. et al. Features of the course of non-alcoholic liver steatosis in women of reproductive age and in menopause. Meditsinskiy sovet = Medical Council. 2022; 16(15): 62–69 (In Russ.)]. https://doi.org/10.21518/2079-701X-2022-16-15-62-69. EDN: LJCDND.
- Трухан Д.И., Иванова Д.С. Неалкогольная жировая болезнь печени, ассоциированная с ожирением: терапевтические возможности. Consilium Medicum. 2016; 18(8): 68–74. [Trukhan D.I., Ivanova D.S. Non-alcoholic fatty liver disease associated with obesity: Therapeutic opportunities. Consilium Medicum. 2016; 18(8): 68–74 (In Russ.)]. EDN: XESUMH.
Supplementary files
